H.C. Wainwright raised the firm’s price target on Cognition Therapeutics (CGTX) to $6 from $5 and keeps a Buy rating on the shares. The company reported positive top-line results from the Phase 2 SHIMMER trial of its lead candidate, the sigma-2 receptor modulator CT1812, in patients suffering from dementia with Lewy bodies, the analyst tells investors in a research note. The firm added the dementia with Lewy bodies indication to its valuation assessment with a 30% likelihood of approval.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics announces results in Phase 2 study of CT1812
- Cognition announces all participants completed final visit in SHIMMER study
- Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis
- Cognition Therapeutics Reports Promising Q3 2024 Results
- Cognition Therapeutics reports Q3 EPS (25c), consensus (22c)